← Leaderboards
Ke Zhang
Northeastern University
$7,536,805
Attributed
$7,536,805
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,536,805 · 3
By mechanism
R01$5,063,751 · 2
R42$2,473,054 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoNucleic AcidsStructureOligonucleotidesBiological ProductsTherapeutic AgentsPropertyProteinsBindingBlood Coagulation DisordersCharacteristicsExhibitsUptakeImmune SystemCellsPolymersModalitySafetySideSide EffectStemNanoparticleLiverToxic Effect
Grant awards (19)
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$473,940
R01 · FY2025 · GM · contact PI
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent$988,000
R42 · FY2024 · CA · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$473,599
R01 · FY2024 · GM · contact PI
Targeting Oncogenic KRAS with Brush-Architectured Poly(ethylene glycol)-DNA Conjugates$355,927
R01 · FY2024 · CA · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$88,145
R01 · FY2024 · GM · contact PI
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent$1,030,054
R42 · FY2023 · CA · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$485,984
R01 · FY2023 · GM · contact PI
Targeting Oncogenic KRAS with Brush-Architectured Poly(ethylene glycol)-DNA Conjugates$367,167
R01 · FY2023 · CA · contact PI
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent$55,000
R42 · FY2023 · CA · contact PI
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent$400,000
R42 · FY2022 · CA · contact PI
Targeting Oncogenic KRAS with Brush-Architectured Poly(ethylene glycol)-DNA Conjugates$367,167
R01 · FY2022 · CA · contact PI
Targeting Oncogenic KRAS with Brush-Architectured Poly(ethylene glycol)-DNA Conjugates$374,660
R01 · FY2021 · CA · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$311,457
R01 · FY2021 · GM · contact PI
Targeting Oncogenic KRAS with Brush-Architectured Poly(ethylene glycol)-DNA Conjugates$388,910
R01 · FY2020 · CA · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$308,666
R01 · FY2020 · GM · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$127,559
R01 · FY2020 · GM · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$312,400
R01 · FY2019 · GM · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$309,768
R01 · FY2018 · GM · contact PI
Making Oligonucleotides Better Biopharmaceuticals by Steric Protection$318,402
R01 · FY2017 · GM · contact PI